SOL.MI Stock Analysis
SO
Avoid
Based on Eyestock quantitative analysis, SOL.MI`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
SOL SpA engages in the production, research, and distribution of industrial and medicinal gases; door-to-door medical care; and related medical equipment. The company is headquartered in Monza, Monza E Brianza and currently employs 5,235 full-time employees. The company is also involved in the home care medical business. The Company’s product portfolio includes oxygen, nitrogen, hydrogen, argon, sulfur hexafluoride, carbon dioxide, ozone, helium and mixtures of medicinal gases, among others. Through its subsidiaries, the Company is involved in the provision of home care services, such as oxygen therapy, mechanical ventilation, diagnosis and care of obstructive sleep apnea syndrome, artificial nutrition, telemedicine, health assistance, and the prevention and treatment of skin ulcers. Additionally, it is engaged in the supply and management of medical and technological devices for home care. As of December 31, 2011, the Company had a number of subsidiaries, including Airsol BV, Biotechsol Srl, CTS Srl, Energetika ZJ doo, GTH Gaze Industriale SA, Cryolab Srl, GTS Shpk and Hydroenergy Shpk, among others.